A zone-based shared-tree multicast protocol for mobile ad hoc networks

This paper proposes a new multicast protocol for mobile ad hoc networks (MANETs). The proposed protocol, Shared-Tree MZR, is a shared tree variant of the Multicast Routing Protocol based on Zone Routing (MZR). The concept of zone-based multicast routing for mobile ad hoc networks was originally proposed in MZR. The new protocol utilizes the advantages of the shared-tree together with the advantages of the zone-based routing. The performance of the protocol is analyzed for various network conditions. The test results show that the new protocol performs well and has significantly low overhead in scenarios with multiple sources

Indirect torque observer-based sensor-less efficient control of bearingless switched reluctance motor using global sliding mode and square currents control method

The Bearingless Switched Reluctance Motor (BSRM) is a new technology motor, which overcomes the problems of maintenances required associated with mechanical contacts and lubrication of rotor shaft effectively. In addition, it also improves the output power developed and rated speed. Hence, the BSRM can achieve high output power and super high speed with less size and cost. It has a considerable ripple in the net-torque due to its critical non-linearity and the salient pole structures of both stator and rotor poles. The resultant torque ripple, especially in these motors, causes the more vibrations and acoustic noises will affects the levitated rotor safety also. Practically at high-speed operations, the accurate measurement of the rotor position is complicated for conventional mechanical sensors. A new square currents control with global sliding mode control based sensorless torque observer is proposed to minimize the torque ripple and achieve a smooth, robust operation without using any mechanical sensors. The proposed controller is designed based on the error between the reference and measured torque values. The sliding mode torque observer measures the torque from the actual phase voltages, currents, and look-up tables. The simulation model has been modelled to validate the proposed methodology. From the simulation outputs, it is clear that the reduction of torque ripple by the method shows improved than the conventional sliding mode controller. The overall system is more robust to the external disturbances, and it also gets efficient torque profile

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Indigenous Knowledge and Health Seeking Behavior Among Kattunayakan: A Tribe in Transition GJHSS-A Classification : FOR Code: 160199 Indigenous Knowledge and Health Seeking Behavior Among KattunayakanA Tribe in Transition Indigenous Knowledge and Health S

Abstract -&quot;This study aimed to document the INDIGENOUS KNOWLEDGE AND HEALTH SEEKING BEHAVIOR of kattunayakan of south &amp; north arcot district, Tamilnadu focusing on their utilization of medicinal plants and associated indigenous knowledge. Five villages were selected out off 65 villages, the participant observation method used for collecting data. Different parts of different Plant are used to treat different ailments ranging from diseases. In an average, the diverse patterns of use of different medicinal plant parts show the considerable indigenous knowledge of kattunayakans.&quot